Lisvy®
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
Description: One patch applied once per week for three weeks (21 days) followed by one week without patch per cycle. Each patch contains 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene.
Product Details
Duration: One week
Regimen:
Dose: 0.02mg EE and 0.05mg gestodene per day
Active Pharmaceutical Ingredient (API):
Status Details
Developer: , ,
Status Details: - This patch was approved in the EU in 2014 and was outlicensed by Bayer to Gedeon Richter, a Hungarian Pharma company. Market entry occurred in late 2015, under the name Lisvy®.
- Product was withdrawn in October 2016 over concerns about the results of a stability test run by Bayer.
- This patch was approved in the EU in 2014 and was outlicensed by Bayer to Gedeon Richter, a Hungarian Pharma company. Market entry occurred in late 2015, under the name Lisvy®.
- Product was withdrawn in October 2016 over concerns about the results of a stability test run by Bayer.
Additional Information
References: Gedeon Richter Plc. website: http://www.richter.hu/en-US/investors/announcements/Pages/extraord150127...
Gedeon Richter Plc. website: http://www.richter.hu/en-US/investors/announcements/Pages/extraord150127...